Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome

OBJECTIVES: Benzodiazepines (BZDs) are the first-line drugs in alcohol-withdrawal syndrome (AWS). Baclofen, a gamma-aminobutyric acid(B) (GABA(B)) agonist, controls withdrawal symptoms without causing significant adverse effects. The objective of this study was to compare the cost-effectiveness of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Vikram K., Girish, K., Lakshmi, Pandit, Vijendra, R., Kumar, Ajay, Harsha, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118528/
https://www.ncbi.nlm.nih.gov/pubmed/25097273
http://dx.doi.org/10.4103/0253-7613.135947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118528/
https://www.ncbi.nlm.nih.gov/pubmed/25097273
http://dx.doi.org/10.4103/0253-7613.135947

Ejemplares similares